Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes

Recombinant adeno-associated viruses (rAAVs) have emerged as one of the most promising gene therapy vectors that have been successfully used in pre-clinical models of heart disease. However, this has not translated well to humans due to species differences in rAAV transduction efficiency. As a resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Cindy Y., Tsurusaki, Shinya, Cabanes-Creus, Marti, Igoor, Sindhu, Rao, Renuka, Skelton, Rhys, Liao, Sophia H.Y., Ginn, Samantha L., Knight, Maddison, Scott, Suzanne, Mietzsch, Mario, Fitzsimmons, Rebecca, Miller, Jessica, Mohamed, Tamer M.A., McKenna, Robert, Chong, James J.H., Hill, Adam P., Hudson, James E., Alexander, Ian E., Lisowski, Leszek, Kizana, Eddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477751/
https://www.ncbi.nlm.nih.gov/pubmed/37674904
http://dx.doi.org/10.1016/j.omtm.2023.08.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477751/
https://www.ncbi.nlm.nih.gov/pubmed/37674904
http://dx.doi.org/10.1016/j.omtm.2023.08.010

Ejemplares similares